Status:

COMPLETED

Ontogeny of Measles Immunity in Infants

Lead Sponsor:

Stanford University

Conditions:

Measles

Eligibility:

All Genders

6+ years

Brief Summary

This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 ...

Detailed Description

This is an open-label immunogenicity and safety study of live attenuated Measles Vaccine (Attenuvax) and Measles-Mumps-Rubella (MMR-II) vaccine administered to healthy children at 6 (n=70), 9 (n=70), ...

Eligibility Criteria

Inclusion

  • Subjects must meet all of the following criteria in order to be enrolled:
  • Healthy infants 6, 9, or 12 months (+ 3 weeks) of age
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study
  • Parent/legal guardian willing and capable of signing written informed consent
  • Parent/legal guardian expected to be available for entire study
  • Parent/legal guardian can be reached by telephone

Exclusion

  • All subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation:
  • Former premature infants (\<36 weeks)
  • Birth weight \< 2500grams
  • Significant underlying chronic illness
  • Immunodeficiency disease or immunosuppressive therapy in the participant
  • Any other condition which in the clinical judgment of the investigator might interfere with vaccine evaluation
  • Allergy to any components of the vaccine, including anaphylaxis or anyphalaxoid reaction to neomycin or eggs
  • Administration of an investigational drug
  • Blood products within 3 months of initial enrollment
  • Current febrile respiratory illness or other active febrile infection
  • Family history of congenital/hereditary immunodeficiency, unless immune competence of subject has been determined.
  • Blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the bone marrow or lymphatic systems.

Key Trial Info

Start Date :

July 1 1993

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2013

Estimated Enrollment :

750 Patients enrolled

Trial Details

Trial ID

NCT00240916

Start Date

July 1 1993

End Date

July 1 2013

Last Update

June 9 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Palo Alto Medical Foundation/Department of Pediatrics

Palo Alto, California, United States, 94301

2

Stanford University School of Medicine

Stanford, California, United States, 94305